The Patient-Focused Medicines Development (PFMD) group, established in 2015, is an independent multinational coalition, managed by The Synergist. Its goal is to bring together initiatives and best practices that integrate the voice of the patient throughout the lifecycle of medicines development, thereby speeding up the creation and implementation of an effective, globally standardized framework.
PFMD seeks to have a balanced representation of stakeholders to ensure transparency, inclusiveness, and credibility in the co-creation processes. Stakeholders include patients and patient organisations across diverse areas of health and industry, lice science companies, research and academia, HTA and regulators, payers and other professional organisations. This ensures the diversity of perspectives.
PFMD works on multiple projects simultaneously, which all aim at driving public and patient involvement and engagement forward.
Problems addressed by Initiative
Medicines are developed to improve the lives of patients. By involving patients throughout the development process, drug trials can be designed to better reflect patient needs and accommodate the challenges they face. This can lead to improved participation rates in trials, help the development of innovative medicines, allow more rapid access to new therapies, and improve health outcomes for patients.
Serving patients in the best way possible requires a deep understanding of their medical condition, which can be can be gained only through direct, sustained and constructive interactions with patients. Health stakeholders have converged on the idea that broadening patient engagement is key to improving drug development.
While stakeholders have started to develop guidelines and methodologies to improving patient engagement in medicines development, this is still in its infancy, and existing approaches are fragmented. An efficient, measurable and reliable framework that involves patients as partners has yet to be developed, validated and applied.